Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Multiple Sclerosis (Jun 2017)

Posted by Matt Breese on Jun 29, 2017

Find me on:

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for multiple sclerosis treatments shows a slight increase in restricted lives over the past 2 quarters. While pharmacy benefit applies to the most treatments, medical benefit coverage is relevant for at least 2 treatments.

mmit-reality-check-ms-2q2017.png

MMIT data current as of Q2 2017 

Trends: Recently approved approved Ocrevus is the fourth infused product approved and the only drug approved to treat progressive forms of MS. Another trend is the overall increase in prescribing of MS products within the long term care facility settings. Specialty Pharmacy Times call out that last year was the first in which neurologists led the way in scripts in this segment. Check out other prescriber and payer trends below.

To read the full Reality Check on Multiple Sclerosis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 

reality-check-thumbnail-v1-1.png

View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing